IM19 chimeric antigen receptor T cell therapy(Yimiao Medical Technology)

IM19嵌合抗原受体T细胞疗法

Report date: 2026/05/22 20:01:29

Base Information

Drug NameIM19 chimeric antigen receptor T cell therapy(Yimiao Medical Technology)
Drug Alias NameIM19 CAR-TIM19嵌合抗原受体T细胞注射液 （IM19CAR-T细胞注射液）IM19 chimeric antigen receptor T cell therapy(Yimiao Medical Technology)IM19
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoproliferative DisordersGlomerulonephritis, MembranousGlomerulonephritis, IGA +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesBeijing Yimiao Medical Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImunopharm Technology Co LtdBeijing Yimiao Medical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsGlomerulonephritis, MembranousGlomerulonephritis, IGALymphoma, Mantle-Cell +[7] 
Inactive IndicationsLymphoproliferative DisordersHematologic NeoplasmsLymphoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A